Study guide
11.2 Spinal Cord Compression & Neurologic Emergencies
Advanced Oncology Certified Nurse Practitioner AOCNP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the AOCNP Exam 1.2 How to Use This AOCNP Study Guide
2 Chapter 2: Cancer Continuum - Risk, Prevention & Screening
2.1 Cancer Risk Factors, At-Risk Populations & Health Disparities 2.2 Primary Prevention, Vaccination, Chemoprevention & Risk-Reducing Surgery 2.3 Cancer Screening & Early Detection Guidelines 2.4 Screening for Subsequent & Second Primary Malignancies 2.5 Hereditary Cancer Syndromes & Genetic Counseling
3 Chapter 3: Cancer Continuum - Assessment, Diagnosis & Staging
3.1 Diagnostic Workup, Tissue Biopsy & Biomarker Evaluation 3.2 Pathology Interpretation, Histology & Tumor Grading 3.3 Cancer Staging Systems (TNM) & Prognostication Models 3.4 Performance Status, Frailty & Geriatric Assessment
4 Chapter 4: Cancer Continuum - Planning, Coordination & Survivorship
4.1 Established Guidelines for Care & Categories of Evidence 4.2 Individualized Treatment Planning & Molecular Tumor Boards 4.3 Reproductive Planning & Fertility Preservation 4.4 Patient Navigation & Interprofessional Care Coordination 4.5 Survivorship Care Planning & Late Effects Management 4.6 Post-Treatment Surveillance for Cancer Recurrence
5 Chapter 5: Cancer Treatment - Antineoplastic Pharmacology & Chemotherapy
5.1 Antineoplastic Principles, Dosing & Dose Adjustments 5.2 Cytotoxic Chemotherapy Classes & Adverse Effect Management 5.3 Safe Administration, Handling & Infusion Toxicities 5.4 Oral Antineoplastic Therapy: Adherence, Interactions & Monitoring
6 Chapter 6: Cancer Treatment - Targeted, Immuno & Hormonal Therapies
6.1 Targeted Therapies, Tyrosine Kinase Inhibitors & ADCs 6.2 Cancer Immunotherapy, Checkpoint Inhibitors & CAR T-Cell Therapy 6.3 Endocrine & Hormonal Therapies in Oncology
7 Chapter 7: Cancer Treatment - Radiation, Surgery, Regional & Multimodal Therapy
7.1 Radiation Oncology Principles & Toxicity Management 7.2 Surgical Oncology, Perioperative Care & Reconstruction 7.3 Regional & Localized Therapy Administration 7.4 Multimodal Therapy & Treatment Sequencing 7.5 Complementary, Alternative & Integrative Therapies
8 Chapter 8: Cancer Treatment - Transplantation, Clinical Trials & Response
8.1 Hematopoietic Stem Cell Transplantation (HSCT) & Cell Therapy 8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)
9 Chapter 9: Supportive Care - Pain & Controlled Substance Safety
9.1 Cancer Pain Assessment & Comprehensive Analgesic Management 9.2 Controlled Substance Safety & Opioid Stewardship 9.3 Nonpharmacologic & Integrative Symptom Interventions
10 Chapter 10: Supportive Care - Symptom & Comorbidity Management
10.1 Acute, Late & Long-Term Patterns of Treatment-Related Symptoms 10.2 Gastrointestinal Symptom Management (CINV, Mucositis, Diarrhea) 10.3 Hematologic & Neurologic Toxicity Management 10.4 Dermatologic, Metabolic & Fatigue Management 10.5 Cancer-Associated Thrombosis & Anticoagulation 10.6 Comorbid Conditions & Their Interaction With Cancer Treatment 10.7 Palliative Care, Hospice & End-of-Life Management
11 Chapter 11: Oncologic Emergencies
11.1 Superior Vena Cava Syndrome & Structural Emergencies 11.2 Spinal Cord Compression & Neurologic Emergencies 11.3 Metabolic Emergencies: Tumor Lysis Syndrome & Hypercalcemia of Malignancy 11.4 Febrile Neutropenia, Sepsis & Vesicant Extravasation 11.5 Cardiopulmonary & Airway Emergencies 11.6 Hematologic & Endocrine Emergencies: DIC, Leukostasis, Hyperviscosity & SIADH
12 Chapter 12: Psychosocial Issues
12.1 Psychosocial Assessment & Distress Screening in Oncology 12.2 Risk Factors & At-Risk Oncology Populations 12.3 Psychosocial & Emotional Sequelae of Disease and Treatment 12.4 Psychiatric & Psychosocial Comorbidities in Cancer Care 12.5 Caregiver Burden, Support & Community Resources
13 Chapter 13: Professional Practice & Roles of the APRN
13.1 APRN Scope of Practice, Prescriptive Authority & Standards of Care 13.2 Bioethics, Informed Consent & Quality Improvement in Oncology 13.3 Cultural Competence, Implicit Bias & Equitable Oncology Care 13.4 Accreditation Standards & Outcomes of APRN Practice 13.5 Competency Evaluation, Peer Review & Peer Education
11.2 Spinal Cord Compression & Neurologic Emergencies
Key Takeaways Explain This Topic AI
Metastatic Spinal Cord Compression (MSCC) occurs in up to 10% of cancer patients, most commonly arising from prostate, breast, lung, renal cell, and multiple myeloma metastases, with 70% occurring in the thoracic spine.
Progressive localized back pain—worse when recumbent, nocturnal, and radiating in a dermatomal distribution—precedes neurological motor/sensory deficits and autonomic dysfunction by weeks.
Emergency whole-spine contrast-enhanced MRI is the diagnostic gold standard and must be performed immediately upon clinical suspicion.
Systemic high-dose corticosteroids (IV Dexamethasone 10 mg loading bolus followed by 4 mg IV/PO Q6H) must be initiated immediately upon clinical suspicion prior to MRI imaging to reduce vasogenic edema.
Emergent surgical decompression and stabilization followed by radiation therapy is superior to radiation alone for mechanical spinal instability, retropulsed bone fragments, radiation-resistant tumors, or unknown histology (Patchell criteria).
Last updated: October 2026
Spinal Cord Compression & Neurologic Emergencies
Oncologic neurologic emergencies represent critical conditions where tumor expansion directly threatens central nervous system integrity. Among these, Metastatic Spinal Cord Compression (MSCC) is one of the most devastating complications in solid tumor and hematologic oncology, occurring in 5% to 10% of all cancer patients. Because neurological recovery directly correlates with neurological status at the time of intervention, rapid APRN recognition, immediate corticosteroid administration, emergent MRI neuroimaging, and urgent surgical or radiotherapeutic referral are paramount.
1. Pathophysiology & Anatomical Distribution
MSCC occurs when metastatic deposits in the vertebral body expand into the epidural space, or less commonly, when paravertebral masses extend through the intervertebral foramina. As the epidural tumor grows, it causes:
Direct Mechanical Compression : Pressure on the spinal cord, nerve roots, and cauda equina.
Vascular Occlusion : Compression of the epidural venous plexus leading to venous congestion, vasogenic edema, ischemia, arterial occlusion, cellular hypoxia, and irreversible spinal cord infarction.
Anatomical Distribution & Etiology
Thoracic Spine (~70%) : Most frequent site due to small spinal canal diameter and high red marrow blood flow.
Lumbosacral Spine (~20%) .
Cervical Spine (~10%) .
Primary Malignancies : Prostate cancer, breast cancer, lung cancer, renal cell carcinoma, non-Hodgkin lymphoma, and multiple myeloma account for > 80 % >80\% > 80% of MSCC cases.
2. Clinical Presentation & Progressive Deficits
Neurological symptoms follow a predictable temporal sequence. Identifying early prodromal symptoms before motor or autonomic loss occurs is the single most important factor determining functional preservation. Sequence of Neurologic Loss in MSCC:
Progressive Localized Back Pain ──► Motor Weakness & Ataxia ──► Sensory Level Loss ──► Autonomic Dysfunction
(Present in >95% for weeks) (Hyperreflexia, Babinski) (Paresthesias, numbness) (Urinary retention, incontinence)
Clinical Manifestations
Progressive Localized Back Pain : The cardinal initial symptom, present in > 95 % >95\% > 95% of patients, preceding neurological deficits by weeks to months. Characteristics include:
Deep, aching pain localized over the affected spinous process, accentuated by direct percussion.
Exacerbated by lying flat (recumbency increases venous plexal engorgement), coughing, sneezing, or Valsalva maneuvers.
Nocturnal pain waking the patient from sleep.
Radicular pain radiating along specific dermatomes (e.g., girdle-like thoracic pain or radicular leg pain).
Motor Deficits : Symmetrical leg weakness, stiffness, difficulty climbing stairs, or gait ataxia. Physical exam demonstrates upper motor neuron signs below the level of compression (spasticity, hyperreflexia, extensor plantar response / positive Babinski sign).
Sensory Deficits : Numbness, paresthesias, or cold sensations ascending to a distinct dermatomal sensory level (e.g., T10 sensory level at the umbilicus, T4 at the nipple line).
Autonomic Dysfunction : Late, grave clinical manifestation indicating severe cord compromise. Includes urinary hesitancy, urinary retention with overflow incontinence, severe constipation, loss of anal sphincter tone, and fecal incontinence. Once autonomic loss occurs, functional recovery following intervention drops below 20%.
- 3. Urgent Diagnostic Evaluation
- Neuroimaging Protocols
Whole-Spine Contrast-Enhanced Magnetic Resonance Imaging (MRI) : The definitive diagnostic gold standard. Whole-spine imaging is mandatory because up to 30% of patients have non-contiguous, multi-level epidural metastases that are clinically silent.
Emergency Timing : Whole-spine MRI must be performed within 24 hours of suspected MSCC, or emergently within 2 to 4 hours if motor weakness is rapidly evolving or present upon exam.
CT Myelography : Reserved exclusively for patients with absolute contraindications to MRI (e.g., non-MRI compatible pacemakers or severe metallic artifacts).
- 4. Emergency Pharmacotherapy & Therapeutic Interventions Suspected MSCC (Back Pain + Neurological Signs)
- │
- ├─► IMMEDIATE Intervention: Administer IV Dexamethasone 10 mg Bolus
- │ └─► Maintain Dexamethasone 4 mg IV/PO Q6H + H2RA / PPI Gastroprotection
- │
- ├─► Order Urgent Whole-Spine Contrast-Enhanced MRI (within 2-24 hours)
- │
- └─► Multidisciplinary Triage based on MRI & Clinical Criteria
├─► Surgical Decompression + RT (Patchell Criteria: Instability, Bone Displacement, Radioresistant, Unknown Primary)
└─► Radiation Therapy Alone (Radiosensitive tumor [Lymphoma/Myeloma/SCLC], No Instability, Poor Surgical Candidate)
Corticosteroid Protocol
Mechanism : Dexamethasone rapidly reduces vasogenic peritumoral edema, decreases spinal cord vascular permeability, and preserves neurological function.
Dosing : Administer IV Dexamethasone 10 mg loading bolus immediately upon clinical suspicion, prior to sending the patient for MRI imaging. Follow with 4 mg IV or PO every 6 hours (16 mg/day).
High-Dose Regimen (100 mg IV bolus followed by 16 mg PO Q6H): Reserved for patients presenting with acute, rapidly progressive paraparesis or complete paraplegia.
Supportive Care : Co-prescribe a proton pump inhibitor (e.g., omeprazole) for gastroprotection and monitor capillary blood glucose closely.
Surgical Decompression vs. Radiation Therapy
Clinical Parameter Direct Surgical Decompression + RT Radiation Therapy (RT) Alone
Primary Indications Mechanical spinal instability (SINS score ≥ 7 \ge 7 ≥ 7 ), retropulsed bone fragments, radioresistant tumors (renal cell, melanoma, sarcoma), unknown primary requiring tissue. Radiosensitive tumors (myeloma, lymphoma, SCLC), multi-level non-contiguous disease, complete paraplegia > 48 >48 > 48 hours, poor surgical candidate.
Clinical Trial Evidence Supported by the landmark Patchell Randomized Trial : Surgical decompression + RT produced significantly higher ambulation rates (84% vs 57%) and longer survival compared to RT alone. Standard non-invasive treatment modality for stable, radiosensitive cord compression.
Dosing / Regimen Anterior or posterior decompressive surgery with spinal hardware stabilization followed by 30 Gy in 10 fractions RT. Hypofractionated RT (8 Gy single fraction or 20 Gy in 5 fractions) vs standard 30 Gy in 10 fractions.
5. Elevated Intracranial Pressure & Brain Metastases
Increased Intracranial Pressure (ICP) results from space-occupying brain metastases, surrounding vasogenic edema, or obstructive hydrocephalus.
Clinical Manifestations & Diagnostic Signs
Morning headache exacerbated by coughing or bending forward, projectile vomiting without nausea, papilledema, focal neurological deficits, seizures, and altered sensorium.
Cushing's Triad (Impending Brain Herniation) : Classic late triad of Hypertension with widening pulse pressure , Bradycardia , and Irregular respirations .
Emergency Management Protocol
High-Dose Corticosteroids : Dexamethasone 4 to 8 mg IV Q6H to resolve vasogenic cerebral edema.
Hyperosmolar Therapy : For acute herniation, administer Mannitol 20% ( 0.5 – 1.0 g/kg 0.5–1.0\text{ g/kg} 0.5–1.0 g/kg IV over 15–30 min) or Hypertonic 3% Saline bolus.
Definitive Oncology Interventions : Stereotactic Radiosurgery (SRS), Whole Brain Radiation Therapy (WBRT), or surgical resection.